• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三阴性乳腺癌：现有和未来诊断方式的综述。

Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.

机构信息

Institute for Research in Molecular Medicine, Universiti Sains Malaysia, USM, Penang 11800, Malaysia.

Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia.

出版信息

Medicina (Kaunas). 2021 Jan 12;57(1):62. doi: 10.3390/medicina57010062.

DOI:10.3390/medicina57010062
PMID:33445543
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7826673/
Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). It is a highly metastasized, heterogeneous disease that accounts for 10-15% of total breast cancer cases with a poor prognosis and high relapse rate within five years after treatment compared to non-TNBC cases. The diagnostic and subtyping of TNBC tumors are essential to determine the treatment alternatives and establish personalized, targeted medications for every TNBC individual. Currently, TNBC is diagnosed via a two-step procedure of imaging and immunohistochemistry (IHC), which are operator-dependent and potentially time-consuming. Therefore, there is a crucial need for the development of rapid and advanced technologies to enhance the diagnostic efficiency of TNBC. This review discusses the overview of breast cancer with emphasis on TNBC subtypes and the current diagnostic approaches of TNBC along with its challenges. Most importantly, we have presented several promising strategies that can be utilized as future TNBC diagnostic modalities and simultaneously enhance the efficacy of TNBC diagnostic.

摘要

三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌，其雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体 2（HER2）均不表达。它是一种高度转移性、异质性疾病，占所有乳腺癌病例的 10-15%，与非 TNBC 病例相比，其治疗后五年内的预后较差且复发率较高。TNBC 肿瘤的诊断和分型对于确定治疗选择以及为每个 TNBC 患者制定个性化、靶向药物至关重要。目前，TNBC 的诊断是通过影像学和免疫组织化学（IHC）的两步程序进行的，这两个程序都依赖于操作者，并且可能耗时较长。因此，迫切需要开发快速和先进的技术来提高 TNBC 的诊断效率。本文综述了乳腺癌的概述，重点介绍了 TNBC 亚型以及目前 TNBC 的诊断方法及其挑战。最重要的是，我们提出了几种有前途的策略，可以作为未来 TNBC 诊断方式，同时提高 TNBC 诊断的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/8e6f739de27b/medicina-57-00062-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/99ed568a06d8/medicina-57-00062-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/73fe17c522d8/medicina-57-00062-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/251f3ad5bb29/medicina-57-00062-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/8e6f739de27b/medicina-57-00062-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/99ed568a06d8/medicina-57-00062-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/73fe17c522d8/medicina-57-00062-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/251f3ad5bb29/medicina-57-00062-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b523/7826673/8e6f739de27b/medicina-57-00062-g004.jpg

相似文献

1
Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.三阴性乳腺癌：现有和未来诊断方式的综述。
Medicina (Kaunas). 2021 Jan 12;57(1):62. doi: 10.3390/medicina57010062.
2
Triple negative breast cancer: looking for the missing link between biology and treatments.三阴性乳腺癌：探寻生物学与治疗之间缺失的环节
Oncotarget. 2015 Sep 29;6(29):26560-74. doi: 10.18632/oncotarget.5306.
3
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.猫乳腺基底样腺癌：一种具有基底样亚型的人类三阴性乳腺癌（TNBC）的潜在模型。
BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.
4
Triple-negative breast cancer molecular subtyping and treatment progress.三阴性乳腺癌分子分型及治疗进展。
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
5
Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.转录组学和蛋白质组学在三阴性乳腺癌预后评估中的最新进展。
J Cell Mol Med. 2022 Mar;26(5):1351-1362. doi: 10.1111/jcmm.17124. Epub 2022 Feb 11.
6
Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.SIRT1、SIRT3 和 SIRT6 基因的表达对三阴性和激素受体阳性乳腺癌亚型生存的预测作用。
Pathol Oncol Res. 2020 Oct;26(4):2723-2731. doi: 10.1007/s12253-020-00873-5. Epub 2020 Jul 17.
7
Triple-negative breast cancer survival in Iranian patients.伊朗患者三阴性乳腺癌的生存率
Acta Med Iran. 2013 Sep 9;51(8):560-6.
8
An overview of triple negative breast cancer for surgical oncologists.外科肿瘤学家视角下的三阴性乳腺癌概述
Surg Oncol. 2015 Sep;24(3):276-83. doi: 10.1016/j.suronc.2015.06.007. Epub 2015 Jun 12.
9
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.细胞角蛋白5/6、雄激素受体和p53的免疫组化共表达状态作为三阴性乳腺癌辅助化疗的预后因素
Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.
10
Genetic Markers in Triple-Negative Breast Cancer.三阴性乳腺癌的遗传标志物。
Clin Breast Cancer. 2018 Oct;18(5):e841-e850. doi: 10.1016/j.clbc.2018.07.023. Epub 2018 Aug 4.

引用本文的文献

1
Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.解析三阴性乳腺癌患者乳腺组织中的新型微生物参与者：荟萃分析视角
NPJ Biofilms Microbiomes. 2025 Sep 9;11(1):182. doi: 10.1038/s41522-025-00816-5.
2
From Structure to Function: The Impact of EGFR and IGF-IR in 3D Breast Cancer Spheroids.从结构到功能：表皮生长因子受体（EGFR）和胰岛素样生长因子1受体（IGF-IR）在三维乳腺癌球体中的作用
Cancers (Basel). 2025 Aug 8;17(16):2606. doi: 10.3390/cancers17162606.
3
Genome-wide discovery of circulating cell-free DNA methylation signatures for the differential diagnosis of triple-negative breast cancer.

本文引用的文献

1
Multimodality Imaging of Breast Parenchymal Density and Correlation with Risk Assessment.乳腺实质密度的多模态成像及其与风险评估的相关性
Curr Breast Cancer Rep. 2019 Mar;11(1):23-33. doi: 10.1007/s12609-019-0302-6. Epub 2019 Jan 17.
2
Triple-negative breast cancer molecular subtyping and treatment progress.三阴性乳腺癌分子分型及治疗进展。
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
3
Re-definition of claudin-low as a breast cancer phenotype.Claudin-low 被重新定义为乳腺癌表型。
全基因组发现循环游离DNA甲基化特征用于三阴性乳腺癌的鉴别诊断
PeerJ. 2025 Aug 20;13:e19888. doi: 10.7717/peerj.19888. eCollection 2025.
4
RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting mA methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype.RBM15通过靶向TNFSF9的mA甲基化并诱导肿瘤相关巨噬细胞极化为M2表型来增强三阴性乳腺癌对紫杉醇的耐药性。
Hereditas. 2025 Aug 19;162(1):167. doi: 10.1186/s41065-025-00534-0.
5
Rare Presentation of Metastatic Breast Cancer Involving the Peritoneal Cavity: Two Cases Arising From Stage 0/1 Disease.转移性乳腺癌累及腹腔的罕见表现：2例起源于0/1期疾病的病例
Cureus. 2025 Jun 17;17(6):e86236. doi: 10.7759/cureus.86236. eCollection 2025 Jun.
6
Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.术前炎症状态作为接受新辅助治疗的三阴性乳腺癌患者的一个积极预后因素。
Medicine (Baltimore). 2025 Jul 11;104(28):e42208. doi: 10.1097/MD.0000000000042208.
7
Single-Cell Transcriptome Analysis Uncovers La Ribonucleoprotein 6 (LARP6) as a Dual Regulator of Proliferation and Immune Infiltration in Triple-Negative Breast Cancer.单细胞转录组分析揭示La核糖核蛋白6（LARP6）作为三阴性乳腺癌增殖和免疫浸润的双重调节因子。
J Cell Mol Med. 2025 Jul;29(13):e70709. doi: 10.1111/jcmm.70709.
8
MicroRNA-driven organ-specific metastasis in triple-negative breast cancer: biogenesis, mechanisms, and therapeutic approaches.微小RNA驱动的三阴性乳腺癌器官特异性转移：生物发生、机制及治疗方法
Med Oncol. 2025 Jun 28;42(8):296. doi: 10.1007/s12032-025-02846-7.
9
Estrogen receptor alpha dynamics and plasticity during endocrine resistance.内分泌抵抗期间雌激素受体α的动力学与可塑性
Biol Direct. 2025 Jun 13;20(1):70. doi: 10.1186/s13062-025-00653-8.
10
Inhibition of ATG5-mediated autophagy maintains PMAIP1 stability to promote cell apoptosis and suppress triple-negative breast cancer progression.抑制自噬相关蛋白5（ATG5）介导的自噬可维持PMAIP1的稳定性，从而促进细胞凋亡并抑制三阴性乳腺癌进展。
Discov Oncol. 2025 May 8;16(1):687. doi: 10.1007/s12672-025-02470-x.
Nat Commun. 2020 Apr 14;11(1):1787. doi: 10.1038/s41467-020-15574-5.
4
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.TTK 抑制通过损伤同源重组增强基底样乳腺癌的放射敏感性。
J Clin Invest. 2020 Feb 3;130(2):958-973. doi: 10.1172/JCI130435.
5
Calcification Microstructure Reflects Breast Tissue Microenvironment.钙化的微观结构反映了乳腺组织的微观环境。
J Mammary Gland Biol Neoplasia. 2019 Dec;24(4):333-342. doi: 10.1007/s10911-019-09441-3. Epub 2019 Dec 5.
6
RAS as Supporting Actor in Breast Cancer.RAS在乳腺癌中作为配角。
Front Oncol. 2019 Nov 12;9:1199. doi: 10.3389/fonc.2019.01199. eCollection 2019.
7
Understanding indications and defining guidelines for breast magnetic resonance imaging.了解乳腺磁共振成像的适应证并制定相关指南。
SA J Radiol. 2018 Oct 30;22(2):1353. doi: 10.4102/sajr.v22i2.1353. eCollection 2018.
8
Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer.CENPF的过表达与乳腺癌的不良预后和肿瘤骨转移相关。
Cancer Cell Int. 2019 Oct 11;19:264. doi: 10.1186/s12935-019-0986-8. eCollection 2019.
9
Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR.使用 4 重数字液滴 PCR 进行乳腺癌亚型分类。
Clin Chem. 2019 Aug;65(8):1051-1059. doi: 10.1373/clinchem.2019.302315. Epub 2019 Apr 22.
10
Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management.转移性乳腺癌细针穿刺物中的激素受体和人表皮生长因子（HER2）表达——在患者管理中的作用
J Cytol. 2019 Apr-Jun;36(2):94-100. doi: 10.4103/JOC.JOC_117_18.